Excerpt: … the European Medicines Agency was to provide a definitive assessment yesterday.“It is difficult to tell exactly how much negative impact this will have on SK Bioscience,” analyst Douglas Kim said in a note on investment research network Smartkarma …
Taipei Times – Business • (Opens in a new window) ⧉
Are you a Professional Journalist?
The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.
